×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ESPR – esperion therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ESPR
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/11
06:00 pm
espr
Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
1/5
08:40 am
espr
Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/5
08:00 am
espr
Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference
12/19
08:00 am
espr
Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes
Low
Report
Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes
12/9
07:36 pm
espr
Why The Narrative Around Esperion Therapeutics Is Shifting After Analyst Upgrades And Trial Results [Yahoo! Finance]
Low
Report
Why The Narrative Around Esperion Therapeutics Is Shifting After Analyst Upgrades And Trial Results [Yahoo! Finance]
12/9
04:30 pm
espr
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Low
Report
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11/26
06:43 am
espr
Esperion Therapeutics (NASDAQ:ESPR) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
Medium
Report
Esperion Therapeutics (NASDAQ:ESPR) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
Date
Time
Symbol
Company Name
Action
%Chg
11/6/2025
06:00 am
ESPR
esperion therapeutics, inc.
MISS
Report
-4.2%
esperion therapeutics, inc.
8/5/2025
06:00 am
ESPR
esperion therapeutics, inc.
BEAT
Report
-0.6%
esperion therapeutics, inc.
5/6/2025
06:00 am
ESPR
esperion therapeutics, inc.
MISS
Report
-5.3%
esperion therapeutics, inc.
3/4/2025
06:00 am
ESPR
esperion therapeutics, inc.
BEAT
Report
12.0%
esperion therapeutics, inc.
Date
Time
Symbol
Headline
Impact
1/12
08:01 am
espr
Form 8-K Esperion Therapeutics, For: Jan 11
High
Report
Form 8-K Esperion Therapeutics, For: Jan 11
12/18
04:10 pm
espr
Form 4 Esperion Therapeutics, For: Dec 17 Filed by: Koenig Sheldon L.
Medium
Report
Form 4 Esperion Therapeutics, For: Dec 17 Filed by: Koenig Sheldon L.
12/18
04:09 pm
espr
Form 4 Esperion Therapeutics, For: Dec 17 Filed by: Looker Benjamin
Medium
Report
Form 4 Esperion Therapeutics, For: Dec 17 Filed by: Looker Benjamin
12/18
04:09 pm
espr
Form 4 Esperion Therapeutics, For: Dec 17 Filed by: Halladay Benjamin
Medium
Report
Form 4 Esperion Therapeutics, For: Dec 17 Filed by: Halladay Benjamin
12/17
03:52 pm
espr
Form 144 Esperion Therapeutics, Filed by: Koenig Sheldon L.
Low
Report
Form 144 Esperion Therapeutics, Filed by: Koenig Sheldon L.
12/17
03:26 pm
espr
Form 144 Esperion Therapeutics, Filed by: Looker Benjamin
Neutral
Report
Form 144 Esperion Therapeutics, Filed by: Looker Benjamin
12/17
03:18 pm
espr
Form 144 Esperion Therapeutics, Filed by: Halladay Benjamin
Low
Report
Form 144 Esperion Therapeutics, Filed by: Halladay Benjamin
12/8
04:27 pm
espr
Form 4 Esperion Therapeutics, For: Dec 04 Filed by: Harlow John B. Jr.
Medium
Report
Form 4 Esperion Therapeutics, For: Dec 04 Filed by: Harlow John B. Jr.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/18
Form 8-K Esperion Therapeutics, For: Mar 14
18.2%
3/17 Esperion Therapeutics Inc (NASDAQ: ESPR) was upgraded by analysts at Citigroup Inc from a "neutral" rating to a "buy" rating. 14.6%
5/5 Esperion Announces U.S. FDA Acceptance of New Drug Applications (NDAs) for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet for Filing and Regulatory Review 11.6%
11/17 Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific Sessions 10.0%
4/20 Esperion Announces Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of NEXLETOL™ (bempedoic acid) and NEXLIZET™ (bempedoic acid and ezetimibe) Tablets in Japan 7.2%
1/31 Form 8-K Esperion Therapeutics, For: Jan 31 6.6%
2/12 Form SC 13G/A Esperion Therapeutics, Filed by: VANGUARD GROUP INC 5.9%
2/28 Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 5.2%
4/16 Form DEF 14A Esperion Therapeutics, For: May 28 4.6%
3/23 Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of the NEXLETOL™ (bempedoic acid) Tablet and Phase 2 Study Results of the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet to be Presented at the American College of Cardiol 4.5%
3/17 Esperion Therapeutics Inc (NASDAQ: ESPR) was upgraded by analysts at Citigroup Inc from a "neutral" rating to a "buy" rating. 14.6%
5/5 Esperion Announces U.S. FDA Acceptance of New Drug Applications (NDAs) for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet for Filing and Regulatory Review 11.6%
11/17 Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific Sessions 10.0%
4/20 Esperion Announces Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of NEXLETOL™ (bempedoic acid) and NEXLIZET™ (bempedoic acid and ezetimibe) Tablets in Japan 7.2%
1/31 Form 8-K Esperion Therapeutics, For: Jan 31 6.6%
2/12 Form SC 13G/A Esperion Therapeutics, Filed by: VANGUARD GROUP INC 5.9%
2/28 Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 5.2%
4/16 Form DEF 14A Esperion Therapeutics, For: May 28 4.6%
3/23 Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of the NEXLETOL™ (bempedoic acid) Tablet and Phase 2 Study Results of the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet to be Presented at the American College of Cardiol 4.5%
TOP News Decliners
2/27
Esperion Provides Lipid Management Franchise Updates; Reports Fourth Quarter and Full Year 2019 Financial Results
-11.2%
3/12 Form 4 Esperion Therapeutics, For: Mar 11 Filed by: MAYLEBEN TIMOTHY M -10.3%
4/1 Esperion Therapeutics Inc (NASDAQ: ESPR) is now covered by analysts at Bank of America Corp. They set a "buy" rating and a price target on the stock. -9.3%
11/6 Q3/2019 9/30/2019 EPS -2.520 ZacksConsensus -2.010 ActVsEst (0.510) - Miss -8.6%
3/31 Esperion Therapeutics Inc (NASDAQ: ESPR) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -7.9%
4/30 Esperion to Report First Quarter 2020 Financial Results May 6, 2020 -7.9%
1/24 Esperion Therapeutics Inc (NASDAQ: ESPR) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -5.3%
2/25 Esperion Therapeutics: The Path After FDA Approval [Seeking Alpha] -4.8%
8/30 Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) -4.7%
2/14 Esperion Therapeutics Inc (NASDAQ: ESPR) was downgraded by analysts at Citigroup Inc from a "buy" rating to a "neutral" rating. -4.5%
3/12 Form 4 Esperion Therapeutics, For: Mar 11 Filed by: MAYLEBEN TIMOTHY M -10.3%
4/1 Esperion Therapeutics Inc (NASDAQ: ESPR) is now covered by analysts at Bank of America Corp. They set a "buy" rating and a price target on the stock. -9.3%
11/6 Q3/2019 9/30/2019 EPS -2.520 ZacksConsensus -2.010 ActVsEst (0.510) - Miss -8.6%
3/31 Esperion Therapeutics Inc (NASDAQ: ESPR) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -7.9%
4/30 Esperion to Report First Quarter 2020 Financial Results May 6, 2020 -7.9%
1/24 Esperion Therapeutics Inc (NASDAQ: ESPR) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -5.3%
2/25 Esperion Therapeutics: The Path After FDA Approval [Seeking Alpha] -4.8%
8/30 Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) -4.7%
2/14 Esperion Therapeutics Inc (NASDAQ: ESPR) was downgraded by analysts at Citigroup Inc from a "buy" rating to a "neutral" rating. -4.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: